Nicorette Mint Notes Soy Allergy; Glaxo/Novartis JV Logo Added To Line
This article was originally published in The Tan Sheet
With Nicorette Lozenge a reference listed drug, labeling for private label equivalents of the mint-flavored version likely also will be changed to include the warning for soy. FDA also approves for all Nicorette products a logo for GlaxoSmithKline Consumer Healthcare L.P., the name of the Glaxo/Novartis JV.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.